Jean Adams v. Merck Sharp & Dohme Corp., et al
| In re: INCRETIN-BASED THERAPIES PRODUCTS LIABILITY LITIGATION |
| JEAN ADAMS, On Behalf of Herself and All Other Similarly Situated Plaintiffs |
| MERCK SHARP & DOHME CORP., FKA Merck & Co. Inc., AMYLIN PHARMACEUTICALS, INC., ELI LILLY AND COMPANY and NOVO NORDISK A/S |
| 22-55095 |
| January 19, 2022 |
| U.S. Court of Appeals, Ninth Circuit |
| Torts - Personal Injury |
Docket Report
RSS Track this Docket
This docket was last retrieved on March 11, 2022. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 9 Terminated Kenneth J. King for Eli Lilly and Company in 22-55095 [12392558] (QDL) [Entered: 03/11/2022 10:40 AM] |
| Filing 8 ENTRY UPDATED. Mail returned on 03/10/2022 addressed to Kenneth J. King, Esquire for Eli Lilly and Company, re: [ # 7 ] Mediation Order. Returned envelope notes: return to sender, no longer here, not deliverable as addressed, unable to forward. Resending to: case files; counsel's ECF account is suspended, appellee is represented by co-counsel. [12392556]--[Edited 03/11/2022 by QDL] (QDL) [Entered: 03/11/2022 10:40 AM] |
| Filing 7 Filed order MEDIATION (SL): This appeal is stayed pending a decision in No. 21-55342. Within 14 days after this court decides No. 21-55342, counsel are requested to send an update to the undersigned (Stephen_Liacouras@ca9.uscourts.gov). [12379661] (AF) [Entered: 02/24/2022 05:21 PM] |
| Filing 6 MEDIATION CONFERENCE Canceled - AssessmentConference, 02/18/2022; 10:00 a.m. Pacific Time. [12374389] (VS) [Entered: 02/18/2022 09:59 AM] |
| Filing 5 MEDIATION CONFERENCE SCHEDULED - DIAL-IN AssessmentConference, 02/18/2022, 10:00 a.m., PACIFIC Time. The briefing schedule previously set by the court remains in effect. See order for instructions and details. [12355623] (VS) [Entered: 01/31/2022 09:25 AM] |
| Filing 4 The Mediation Questionnaire for this case was filed on 01/26/2022. To submit pertinent confidential information directly to the Circuit Mediators, please use the following # link . Confidential submissions may include any information relevant to mediation of the case and settlement potential, including, but not limited to, settlement history, ongoing or potential settlement discussions, non-litigated party related issues, other pending actions, and timing considerations that may impact mediation efforts.[12351991]. [22-55095] (AD) [Entered: 01/26/2022 12:44 PM] |
| Filing 3 Filed (ECF) Appellant Jean Adams Mediation Questionnaire. Date of service: 01/26/2022. [12351650] [22-55095] (Johnson, Michael) [Entered: 01/26/2022 10:18 AM] |
| Filing 2 Received copy of amended notice of appeal from district court. [12345356] (NAC) [Entered: 01/20/2022 07:17 AM] |
| Filing 1 DOCKETED CAUSE AND ENTERED APPEARANCES OF COUNSEL. SEND MQ: Yes. The schedule is set as follows: Appellant Jean Adams Mediation Questionnaire due on 01/26/2022. Transcript ordered by 02/17/2022. Transcript due 03/21/2022. Appellant Jean Adams opening brief due 04/25/2022. Appellees Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Merck Sharp & Dohme Corp. and Novo Nordisk A/S answering brief due 05/25/2022. Appellant's optional reply brief is due 21 days after service of the answering brief. [12345187] (RT) [Entered: 01/19/2022 04:39 PM] |
Access additional case information on PACER
Access the Case Summary and Docket Report to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
